[Special Stock] Wonik Holdings Rises on Spotlight as Investor Holds Patent for COVID-19 Related Pediatric Syndrome

[Asia Economy Reporter Minwoo Lee] Wonik Holdings' stock price is on the rise. This appears to be due to news that a company invested in by its subsidiary holds patents related to infant mysterious disease.

As of 3 PM on the 26th, Wonik Holdings' stock price is recorded at 5,050 KRW, up 6.88% from the previous day. The news of securing related patents gained attention just one day after the quarantine authorities activated a surveillance system for pediatric multisystem inflammatory syndrome, commonly called 'children's mysterious disease,' and suspected cases appeared.

Earlier, the Central Disease Control Headquarters announced that as of midnight on the same day, two suspected cases of this children's mysterious disease were reported. However, both patients tested negative in the polymerase chain reaction (PCR) tests for COVID-19.

This disease was first discovered in Europe in April and has been spreading mainly in the United States and Europe. As of the 23rd, it has occurred in 13 countries. It shows symptoms similar to Kawasaki disease, an acute febrile rash illness usually occurring in infants under 4 years old, and in severe cases, it is known to be fatal. The exact cause is still unknown.

Meanwhile, Medizen Human Care, invested in by Wonik Investment Partners, a subsidiary of Wonik Holdings, uniquely holds three patents in Korea related to the diagnosis and prediction of Kawasaki disease, a type of mysterious disease affecting infants.

This content was produced with the assistance of AI translation services.